Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study

Jenny L Schnyder; Kim van Sinderen; Nita Schipper-Boer; Sanne Terryn; Inne Nauwelaers; Cornelis Stijnis; Martin P Grobusch; Abraham Goorhuis

doi:10.1093/jtm/taaf085

Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study

Jenny L Schnyder
, Kim van Sinderen
, Nita Schipper-Boer
, Sanne Terryn
, Inne Nauwelaers
, Cornelis Stijnis
, Martin P Grobusch
, Abraham Goorhuis

Centre of Tropical Medicine and Travel Medicine
Department of Infectious Diseases
Division of Internal Medicine
Amsterdam University Medical Centre
Central Military Hospital
Sciensano
Saxony Liaison Office Brussels, Brussels, Belgium.

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

In 19 patients on immunosuppressive monotherapy who received rabies pre-exposure prophylaxis (PrEP) whilst immunocompetent, all but one showed boostability (antibodies > 0.5 IU/mL) 7 days after post-exposure prophylaxis (PEP) 1-20 years post-PrEP. Tailoring guidelines for specific immunocompromised patient groups is advisable and may improve vaccine coverage and optimize rabies immunoglobulin use.

Original language	English
Journal	Journal of travel medicine
Volume	32
Issue number	8
DOIs	https://doi.org/10.1093/jtm/taaf085
Publication status	Published - 17 Dec 2025
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Rabies/prevention & control
Immunocompromised Host
Pre-Exposure Prophylaxis/methods
Rabies Vaccines/immunology
Adult
Male
Female
Middle Aged
Immunosuppressive Agents/therapeutic use
Post-Exposure Prophylaxis
Antibodies, Viral/blood
Aged

Access to Document

10.1093/jtm/taaf085

Long-term-immunogenicity-and-boostability-of-rabies-pre-exposure-prophylaxis-prep-in-immunocompromised-adults-who-rece.pdfFinal published version, 378 KBLicence: Taverne

Cite this

Schnyder, J. L., van Sinderen, K., Schipper-Boer, N., Terryn, S., Nauwelaers, I., Stijnis, C., Grobusch, M. P., & Goorhuis, A. (2025). Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study. Journal of travel medicine, 32(8). https://doi.org/10.1093/jtm/taaf085

@article{e37b15d02bc949f99d307b8ff9e7a271,

title = "Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study",

abstract = "In 19 patients on immunosuppressive monotherapy who received rabies pre-exposure prophylaxis (PrEP) whilst immunocompetent, all but one showed boostability (antibodies > 0.5 IU/mL) 7 days after post-exposure prophylaxis (PEP) 1-20 years post-PrEP. Tailoring guidelines for specific immunocompromised patient groups is advisable and may improve vaccine coverage and optimize rabies immunoglobulin use.",

keywords = "Humans, Rabies/prevention \& control, Immunocompromised Host, Pre-Exposure Prophylaxis/methods, Rabies Vaccines/immunology, Adult, Male, Female, Middle Aged, Immunosuppressive Agents/therapeutic use, Post-Exposure Prophylaxis, Antibodies, Viral/blood, Aged",

author = "Schnyder, \{Jenny L\} and \{van Sinderen\}, Kim and Nita Schipper-Boer and Sanne Terryn and Inne Nauwelaers and Cornelis Stijnis and Grobusch, \{Martin P\} and Abraham Goorhuis",

note = "{\textcopyright} The Author(s) 2025. Published by Oxford University Press on behalf of the International Society of Travel Medicine. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].",

year = "2025",

month = dec,

day = "17",

doi = "10.1093/jtm/taaf085",

language = "English",

volume = "32",

journal = "Journal of travel medicine",

issn = "1195-1982",

publisher = "Wiley Blackwell",

number = "8",

}

Schnyder, JL, van Sinderen, K, Schipper-Boer, N, Terryn, S, Nauwelaers, I, Stijnis, C, Grobusch, MP & Goorhuis, A 2025, 'Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study', Journal of travel medicine, vol. 32, no. 8. https://doi.org/10.1093/jtm/taaf085

Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study. / Schnyder, Jenny L; van Sinderen, Kim; Schipper-Boer, Nita et al.
In: Journal of travel medicine, Vol. 32, No. 8, 17.12.2025.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy

T2 - an exploratory study

AU - Schnyder, Jenny L

AU - van Sinderen, Kim

AU - Schipper-Boer, Nita

AU - Terryn, Sanne

AU - Nauwelaers, Inne

AU - Stijnis, Cornelis

AU - Grobusch, Martin P

AU - Goorhuis, Abraham

N1 - © The Author(s) 2025. Published by Oxford University Press on behalf of the International Society of Travel Medicine. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

PY - 2025/12/17

Y1 - 2025/12/17

N2 - In 19 patients on immunosuppressive monotherapy who received rabies pre-exposure prophylaxis (PrEP) whilst immunocompetent, all but one showed boostability (antibodies > 0.5 IU/mL) 7 days after post-exposure prophylaxis (PEP) 1-20 years post-PrEP. Tailoring guidelines for specific immunocompromised patient groups is advisable and may improve vaccine coverage and optimize rabies immunoglobulin use.

AB - In 19 patients on immunosuppressive monotherapy who received rabies pre-exposure prophylaxis (PrEP) whilst immunocompetent, all but one showed boostability (antibodies > 0.5 IU/mL) 7 days after post-exposure prophylaxis (PEP) 1-20 years post-PrEP. Tailoring guidelines for specific immunocompromised patient groups is advisable and may improve vaccine coverage and optimize rabies immunoglobulin use.

KW - Humans

KW - Rabies/prevention & control

KW - Immunocompromised Host

KW - Pre-Exposure Prophylaxis/methods

KW - Rabies Vaccines/immunology

KW - Adult

KW - Male

KW - Female

KW - Middle Aged

KW - Immunosuppressive Agents/therapeutic use

KW - Post-Exposure Prophylaxis

KW - Antibodies, Viral/blood

KW - Aged

U2 - 10.1093/jtm/taaf085

DO - 10.1093/jtm/taaf085

M3 - Article

C2 - 40874561

SN - 1195-1982

VL - 32

JO - Journal of travel medicine

JF - Journal of travel medicine

IS - 8

ER -

Long-term immunogenicity and boostability of rabies pre-exposure prophylaxis (PrEP) in immunocompromised adults who received PrEP prior to the start of immunosuppressive therapy: an exploratory study

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this